TREVI THERAPEUTICS INC (TRVI)
US89532M1018 - Common Stock
We assign a fundamental rating of 2 out of 10 to TRVI. TRVI was compared to 198 industry peers in the Pharmaceuticals industry. While TRVI seems to be doing ok healthwise, there are quite some concerns on its profitability. TRVI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
TRVI had negative earnings in the past year.
TRVI had a negative operating cash flow in the past year.
TRVI had negative earnings in each of the past 5 years.
TRVI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TRVI has a Return On Assets (-32.52%) which is in line with its industry peers.
With a decent Return On Equity value of -35.22%, TRVI is doing good in the industry, outperforming 63.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.52% | ||
| ROE | -35.22% | ||
| ROIC | N/A |
ROA(3y)-48.12%
ROA(5y)-51.7%
ROE(3y)-86.94%
ROE(5y)-85.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TRVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for TRVI has been increased compared to 1 year ago.
Compared to 5 years ago, TRVI has more shares outstanding
Compared to 1 year ago, TRVI has an improved debt to assets ratio.
2.2 Solvency
TRVI has an Altman-Z score of 14.33. This indicates that TRVI is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 14.33, TRVI belongs to the best of the industry, outperforming 90.26% of the companies in the same industry.
TRVI has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
TRVI has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.33 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
TRVI has a Current Ratio of 15.03. This indicates that TRVI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 15.03, TRVI belongs to the top of the industry, outperforming 91.28% of the companies in the same industry.
A Quick Ratio of 15.03 indicates that TRVI has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 15.03, TRVI belongs to the best of the industry, outperforming 91.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.03 | ||
| Quick Ratio | 15.03 |
3. Growth
3.1 Past
TRVI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.21%, which is quite impressive.
EPS 1Y (TTM)48.21%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 13.91% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-37.88%
EPS Next 2Y-25.39%
EPS Next 3Y-31.58%
EPS Next 5Y13.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TRVI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRVI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TRVI's earnings are expected to decrease with -31.58% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.39%
EPS Next 3Y-31.58%
5. Dividend
5.1 Amount
TRVI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TREVI THERAPEUTICS INC
NASDAQ:TRVI (5/6/2024, 7:00:02 PM)
2.94
-0.08 (-2.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap202.74M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.52% | ||
| ROE | -35.22% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 15.03 | ||
| Quick Ratio | 15.03 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)48.21%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-37.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y